1. Home
  2. FLNC vs ZYME Comparison

FLNC vs ZYME Comparison

Compare FLNC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluence Energy Inc.

FLNC

Fluence Energy Inc.

HOLD

Current Price

$10.10

Market Cap

1.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$30.53

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNC
ZYME
Founded
2018
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
FLNC
ZYME
Price
$10.10
$30.53
Analyst Decision
Hold
Strong Buy
Analyst Count
17
11
Target Price
$15.71
$38.90
AVG Volume (30 Days)
6.6M
673.2K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$2,262,830,000.00
$105,965,000.00
Revenue This Year
$51.23
$183.10
Revenue Next Year
$21.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
38.87
52 Week Low
$6.60
$14.07
52 Week High
$33.51
$31.17

Technical Indicators

Market Signals
Indicator
FLNC
ZYME
Relative Strength Index (RSI) 32.96 70.44
Support Level N/A $22.26
Resistance Level $15.89 N/A
Average True Range (ATR) 0.53 1.58
MACD 0.02 0.36
Stochastic Oscillator 8.46 94.69

Price Performance

Historical Comparison
FLNC
ZYME

About FLNC Fluence Energy Inc.

Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: